- What are KPIs and how are they used to monitor project progress?
- What are best practices for selecting KPIs?
- What are some ways to visually display KPIs for fast understanding and actionable insights?
Archives: Agenda
Fact vs. Fiction: Debunking common misconceptions about mobile visits
In this session, we’ll address five of the most common myths surrounding mobile visits, replacing assumptions with real-world data and operational insights:
- Consistent clinician assignments build trust and strengthen patient relationships
- Mobile visits can offer greater privacy and comfort than traditional sites
- Decentralized models can accommodate complex protocols without compromising quality
- Structured planning makes mobile visits logistically viable and scalable
- Bringing research directly into communities expands access and improves retention and inclusivity
Navigating the complexities of site relationships: defining roles for sponsors and CROs
- How sponsor and CRO priorities differ, and the importance of clearly defined roles in fostering effective site partnerships
- Key distinctions between site engagement and site management, and how responsibilities should be strategically allocated
- Opportunities for sponsors to strengthen site relationships through proactive engagement and thoughtful collaboration
- Best practices for leveraging CRO networks and KOL partnerships to support site success, particularly in later-phase trials
Importance of effective vendor management in the clinical trial process through teamwork and clarity
- Streamlining vendor management to reduce costs and timelines and to improve overall operational efficiency: Clear communication, defined roles and responsibilities and standardized documentation to enhance accessibility and collaboration
- Mitigating risks associated with compliance, quality, and data integrity and reducing the impact of delays in patient recruitment, data collection, and regulatory submissions on trial budgets and timelines
- Setting specific, measurable KPIs to evaluate vendor performance throughout the trial, focusing on metrics such as patient enrollment rates, data accuracy, and timeline adherence
- Leverage technology for real-time monitoring of trial progress and vendor performance, allowing prompt identification of issues
- Comprehensive evaluation of the closing out the trial process: Aligning goals, timelines and encouraging proactive management of timelines to identify potential bottlenecks early and involve vendors in the resolution process
Lunch and Networking
Chair’s Opening Remarks
KEYNOTE: (Clinical) Trials and Tribulations – Our biotech’s out of US Phase 1 experience
- Voyage of Discovery: Why we crossed the ocean for our FIH Trial
- Speed Dating: Choosing partners for the clinical research dance
- Do You Feel a Draft?: Endless iterations of study-specific documents
- H-Wrecked: navigating unexpected reefs in the journey to study start-up
- Out of Site, Out of Mind
PANEL DISCUSSION: Identifying patients as equal partners and including their voice in all stages of drug development
- Acknowledging the value that patients can bring to every stage of the drug development pathway
- Engaging patients and advocacy groups early on in the clinical trial design process
- How minimizing participant burden leads to on-time enrollment and completion
- Combining patient perspectives with those of healthcare professionals to create a holistic trial model
- Highlighting how to compensate patients
Moderator: Amanda Murphy, Senior Director, Data Intelligence & Solutions, GlobalData